Bepridil

Bepridil

Clinical data
Trade names	Vascor
AHFS/Drugs.com	Monograph
MedlinePlus	a699051
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Oral
ATC code	C08EA02 (WHO)
Pharmacokinetic data
Bioavailability	Well absorbed
Protein binding	99%
Metabolism	Hepatic, CYP3A4-mediated
Biological half-life	42 hours
Excretion	Renal
Identifiers
IUPAC name N-benzyl-N-(3-isobutoxy-2-pyrrolidin-1-yl-propyl)aniline
CAS Number	64706-54-3 Y
PubChem CID	2351
IUPHAR/BPS	2337
DrugBank	DB01244 Y
ChemSpider	2261 Y
UNII	755BO701MA
ChEBI	CHEBI:3061 Y
ChEMBL	CHEMBL1008 Y
Chemical and physical data
Formula	C24H34N2O
Molar mass	366.54 g/mol
3D model (Jmol)	Interactive image
SMILES O(CC(C)C)CC(N1CCCC1)CN(c2ccccc2)Cc3ccccc3
InChI InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3 Y Key:UIEATEWHFDRYRU-UHFFFAOYSA-N Y

Bepridil (trade name Vascor) is an amine calcium channel blocker once used to treat angina. It is no longer sold in the United States.

It is nonselective.

It has been discussed as a possible option in the treatment of atrial fibrillation.

It has been implicated in causing ventricular arrhythmia (torsades de pointes).

In June 2015 a research paper was published finding bepridil to result in a 100% survival rate for mice exposed to ebola during an experiment searching for potential pharmaceutical ebola treatments; indicating its potential use in future ebola research and therapy.